Basic Information
| LncRNA/CircRNA Name | TP73-AS1 |
| Synonyms | TP73-AS1, KIAA0495, PDAM |
| Region | GRCh38_1:3735601-3747336 |
| Ensemble | ENSG00000227372 |
| Refseq | NR_033708 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | cholangiocarcinoma |
| ICD-0-3 | NA |
| Methods | qPCR, Flow cytometry assay, etc. |
| Sample | Human CCA cell lines (HCCC-9810, RBE). CCA tissues. |
| Expression Pattern | up-regulated |
| Function Description | For the part of functional assays, silencing of TP73-AS1 could attenuate CCA cell growth both in vitro and in vivo. Additionally, silencing of TP73-AS1 facilitates apoptosis via activating caspase-3 and caspase-9. Importantly, TP73-AS1 expression did not affect HIBEC cell growth and apoptosis. Moreover, TP73-AS1 could also facilitate migration and invasion potential of CCA cells. reported that TP73-AS1/miR-200a/ZEB1 axis could promote. |
| Pubmed ID | 29966969 |
| Year | 2018 |
| Title | Enhanced expression of lncRNA TP73-AS1 predicts adverse phenotypes for cholangiocarcinoma and exerts oncogenic properties in vitro and in vivo. |
External Links
| Links for TP73-AS1 | GenBank HGNC NONCODE |
| Links for cholangiocarcinoma | OMIM COSMIC |